PMID- 37614958
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230825
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a 
      real-life multicenter study-IL PSO (Italian landscape psoriasis).
PG  - 1243843
LID - 10.3389/fmed.2023.1243843 [doi]
LID - 1243843
AB  - INTRODUCTION: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A 
      and F, approved for the treatment of moderate-to-severe plaque psoriasis. While 
      bimekizumab has been evaluated in several phase-III clinical trials, real-world 
      evidence is still very limited. METHOD: This multicenter retrospective study 
      included patients affected by plaque psoriasis treated with bimekizumab from May 
      1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by 
      moderate-to-severe plaque psoriasis eligible for systemic treatments were 
      included. The effectiveness of bimekizumab was evaluated in terms of reduction in 
      psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 
      16. The main outcomes were the percentages of patients achieving an improvement 
      of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. RESULTS: 
      The study included 237 patients who received at least one injection of 
      bimekizumab. One hundred and seventy-one patients and 114 reached four and 
      16 weeks of follow-up, respectively. Complete skin clearance was achieved by 
      43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of 
      patients reported no impact on their quality of life. At week 16, there were no 
      significant differences between bio-naive and bio-experienced patients in terms 
      of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) 
      were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation 
      were observed throughout the study. CONCLUSION: Our experience supports the 
      effectiveness and tolerability of bimekizumab in a real-world setting with 
      similar results compared with phase-III clinical trials.
CI  - Copyright (c) 2023 Gargiulo, Narcisi, Ibba, Balato, Bianchi, Brianti, Buononato, 
      Burlando, Caldarola, Campanati, Campione, Carrera, Carugno, Cristaudo, Cusano, 
      Dapavo, Dattola, De Simone, Gaiani, Gisondi, Giunta, Loconsole, Maione, Mortato, 
      Marzano, Maurelli, Megna, Mercuri, Offidani, Orsini, Parodi, Pellacani, Potestio, 
      Quaglino, Richetta, Romano, Sena, Venturini, Malagoli and Costanzo.
FAU - Gargiulo, Luigi
AU  - Gargiulo L
AD  - Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy.
FAU - Narcisi, Alessandra
AU  - Narcisi A
AD  - Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
FAU - Ibba, Luciano
AU  - Ibba L
AD  - Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy.
FAU - Balato, Anna
AU  - Balato A
AD  - Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
FAU - Bianchi, Luca
AU  - Bianchi L
AD  - Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - Brianti, Pina
AU  - Brianti P
AD  - Unit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and 
      Institute for Research and Care, Milan, Italy.
FAU - Buononato, Dario
AU  - Buononato D
AD  - Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
FAU - Burlando, Martina
AU  - Burlando M
AD  - Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino 
      University Hospital, Genoa, Italy.
FAU - Caldarola, Giacomo
AU  - Caldarola G
AD  - Section of Dermatology, Department of Translational Medicine and Surgery, 
      Catholic University of the Sacred Heart, Rome, Italy.
AD  - Dermatology Unit, Agostino Gemelli University Hospital, Rome, Italy.
FAU - Campanati, Anna
AU  - Campanati A
AD  - Department of Clinical and Molecular Sciences-Dermatological Clinic, Universita 
      Politecnica delle Marche, Ancona, Italy.
FAU - Campione, Elena
AU  - Campione E
AD  - Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - Carrera, Carlo G
AU  - Carrera CG
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Carugno, Andrea
AU  - Carugno A
AD  - Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
AD  - PhD Program in Molecular and Translational Medicine (DIMET), University of 
      Milan-Bicocca, Milan, Italy.
FAU - Cristaudo, Antonio
AU  - Cristaudo A
AD  - Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, 
      Italy.
FAU - Cusano, Francesco
AU  - Cusano F
AD  - Department of Dermatology, Gaetano Rummo Hospital, Benevento, Italy.
FAU - Dapavo, Paolo
AU  - Dapavo P
AD  - Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, 
      University of Turin, Turin, Italy.
FAU - Dattola, Annunziata
AU  - Dattola A
AD  - Dermatology Clinic, Department of Clinical Internal, Anesthesiological and 
      Cardiovascular Sciences, Sapienza University, Rome, Italy.
FAU - De Simone, Clara
AU  - De Simone C
AD  - Section of Dermatology, Department of Translational Medicine and Surgery, 
      Catholic University of the Sacred Heart, Rome, Italy.
AD  - Dermatology Unit, Agostino Gemelli University Hospital, Rome, Italy.
FAU - Gaiani, Francesca M
AU  - Gaiani FM
AD  - Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato 
      Milanese, Milan, Italy.
FAU - Gisondi, Paolo
AU  - Gisondi P
AD  - Department of Medicine, Section of Dermatology and Venereology, University of 
      Verona, Verona, Italy.
FAU - Giunta, Alessandro
AU  - Giunta A
AD  - Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - Loconsole, Francesco
AU  - Loconsole F
AD  - Department of Dermatology, University of Bari, Bari, Italy.
FAU - Maione, Vincenzo
AU  - Maione V
AD  - Department of Dermatology, ASST Spedali Civili Hospital, Brescia, Italy.
FAU - Mortato, Edoardo
AU  - Mortato E
AD  - Department of Dermatology, University of Bari, Bari, Italy.
FAU - Marzano, Angelo V
AU  - Marzano AV
AD  - Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, Universita degli Studi di 
      Milano, Milan, Italy.
FAU - Maurelli, Martina
AU  - Maurelli M
AD  - Department of Medicine, Section of Dermatology and Venereology, University of 
      Verona, Verona, Italy.
FAU - Megna, Matteo
AU  - Megna M
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Mercuri, Santo R
AU  - Mercuri SR
AD  - Unit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and 
      Institute for Research and Care, Milan, Italy.
FAU - Offidani, Annamaria
AU  - Offidani A
AD  - Department of Clinical and Molecular Sciences-Dermatological Clinic, Universita 
      Politecnica delle Marche, Ancona, Italy.
FAU - Orsini, Diego
AU  - Orsini D
AD  - Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, 
      Italy.
FAU - Parodi, Aurora
AU  - Parodi A
AD  - Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino 
      University Hospital, Genoa, Italy.
FAU - Pellacani, Giovanni
AU  - Pellacani G
AD  - Dermatology Clinic, Department of Clinical Internal, Anesthesiological and 
      Cardiovascular Sciences, Sapienza University, Rome, Italy.
FAU - Potestio, Luca
AU  - Potestio L
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Quaglino, Pietro
AU  - Quaglino P
AD  - Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, 
      University of Turin, Turin, Italy.
FAU - Richetta, Antonio G
AU  - Richetta AG
AD  - Dermatology Clinic, Department of Clinical Internal, Anesthesiological and 
      Cardiovascular Sciences, Sapienza University, Rome, Italy.
FAU - Romano, Francesca
AU  - Romano F
AD  - Department of Precision Medicine, Dermatology Unit, Universita degli Studi della 
      Campania L. Vanvitelli, Naples, Italy.
FAU - Sena, Paolo
AU  - Sena P
AD  - Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
FAU - Venturini, Marina
AU  - Venturini M
AD  - Department of Dermatology, ASST Spedali Civili Hospital, Brescia, Italy.
FAU - Malagoli, Piergiorgio
AU  - Malagoli P
AD  - Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato 
      Milanese, Milan, Italy.
FAU - Costanzo, Antonio
AU  - Costanzo A
AD  - Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230808
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10442506
OTO - NOTNLM
OT  - bimekizumab
OT  - biologics
OT  - psoriasis
OT  - psoriasis treatment
OT  - real-life
COIS- LG has been a consultant for Almirall. PM has been a speaker for AbbVie, Lilly, 
      Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. AB has received 
      honoraria for participation in advisory boards, meetings, or as speaker for 
      AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, 
      Sanofi-Genzyme, and UCB Pharma. LB has received honoraria as a speaker or 
      consultant for AbbVie, Janssen, Almirall Eli-Lilly, Leopharma, Novartis, Sanofi, 
      Pfizer, and UCB Pharma. GC reports consulting fees or honorarium and payment for 
      lectures from Lilly and Novartis. CD reports consulting fees or honorarium from 
      Abbvie, Amgen, Novartis, Celgene, Sanofi, UCB Pharma, Janssen, and Lilly and 
      payment for lectures from Abbvie, Lilly, Novartis, UCB Pharma, and Celgene. PG 
      has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, 
      Leo-Pharma, Eli-Lilly, Novartis, Pierre Febre, Sandoz, Sanofi, and UCB. MB has 
      acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli 
      Lilly, and UCB Pharma. CC has served as a board participant or speaker for 
      Abbvie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leopharma. PD has been a 
      speaker for Novartis, Abbvie, Sanofi, UCB, Janssen, Lilly, and LeoPharma. FG 
      acted as a speaker or consultant for Novartis, Abbvie, Eli Lilly, Celgene, 
      LeoPharma, and Almirall. AG received grants or is an investigator for Biogen and 
      Lilly; and is a consultant/advisory board/speaker for AbbVie, Almirall, Celgene, 
      Janssen, Leo Pharma, Eli Lilly, Merck Sharpe Dohme, Novartis, Pfizer, Sandoz, and 
      UCB. FL served on advisory boards and/or received honoraria for lectures from 
      Abbvie, Janssen-Cilag, Novartis, Lilly, Sanofi. AM reports consultancy/advisory 
      boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, 
      Pfizer, Sanofi, and UCB. MMe acted as a speaker or consultant for Abbvie, Eli 
      Lilly, Janssen, Leo-Pharma, UCB, and Novartis. AO acted as a speaker and 
      consultant for Abbvie, Eli Lilly, Novartis, Celgene, Sanofi, Galderma, Leo 
      Pharma, and Pierre Fabre. MV served as a speaker or advisory board member for 
      Abbvie, Almirall, Amgen, Eli-Lilly, Galderma, Leo Pharma, Novartis, Pierre Fabre, 
      and UCB Pharma. ACo has served as an advisory board member, consultant and has 
      received fees and speaker's honoraria or has participated in clinical trials for 
      Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi 
      Genzyme, and UCB-Pharma. AN has served on advisory boards, received honoraria for 
      lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli 
      Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen, and Boehringer Ingelheim. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/24 06:42
MHDA- 2023/08/24 06:43
PMCR- 2023/08/08
CRDT- 2023/08/24 04:12
PHST- 2023/06/21 00:00 [received]
PHST- 2023/07/27 00:00 [accepted]
PHST- 2023/08/24 06:43 [medline]
PHST- 2023/08/24 06:42 [pubmed]
PHST- 2023/08/24 04:12 [entrez]
PHST- 2023/08/08 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1243843 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. 
      eCollection 2023.